等待开盘 09-24 09:30:00 美东时间
-0.009
-0.03%
The FDA approved AstraZeneca's Koselugo for children 1+ with NF1 and inoperable nerve tumors, expanding treatment options with an established safe dose.
09-11 03:05
Rain Enhancement Technologies Holdco, Inc. received a notice from Nasdaq on August 19, 2025, stating it failed to meet the minimum market value requirements under Nasdaq Listing Rules 5450(b)(2)(A) and 5450(b)(2)(B). The company has until August 26, 2025, to appeal the delisting determination. It requested a hearing before the Nasdaq Hearing Panel on August 21, 2025, to seek additional time to regain compliance. The company plans to present its c...
08-22 20:30